Cumulative lead dose and cognitive function in adults: A review of studies that measured both blood lead and bone lead

Environmental Health Perspectives

Volumn 115, Issue 3, 2007, Pages 483-492

  Shih, Regina A ^a   Hu, Howard ^b,c   Weisskopf, Marc G ^b,c   Schwartz, Brian S ^d,e  

^a EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^e JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adults; Blood; Bone; Cognitive function; Lead; Neurobehavior

Indexed keywords

LEAD;

BLOOD ANALYSIS; BONE LEVEL; COGNITIVE DEFECT; CORRELATION ANALYSIS; DISEASE MARKER; ENVIRONMENTAL EXPOSURE; ENVIRONMENTAL FACTOR; EVIDENCE BASED MEDICINE; GENE INTERACTION; GENETIC RISK; HUMAN; INFORMATION RETRIEVAL; LEAD BLOOD LEVEL; LEAD POISONING; LONGITUDINAL STUDY; MEDICAL INFORMATION; MENTAL DISEASE; MINI MENTAL STATE EXAMINATION; OCCUPATIONAL DISEASE; OCCUPATIONAL EXPOSURE; OCCUPATIONAL HAZARD; OCCUPATIONAL SAFETY; PRIORITY JOURNAL; QUALITY CONTROL; REVIEW; RISK ASSESSMENT; RISK FACTOR; SYMPTOM; SYSTEMATIC REVIEW; TOXIN ANALYSIS;

ADULT; BONE AND BONES; COGNITION; ENVIRONMENTAL POLLUTANTS; HUMANS; LEAD;

EID: 34147173975     PISSN: 00916765     EISSN: 15529924     Source Type: Journal    
DOI: 10.1289/ehp.9786     Document Type: Review

References (86)

1. Agency for Toxic Substances and Disease Registry. 1999. Toxicological Profile for Lead. Update, 1999. Atlanta: Agency for Toxic Substances and Disease Registry.
2. American Psychological Association. 2006. PsychINFO Database. Available: http://www.apa.org/psycinfo/ [accessed 24 August 2006].
3. Annest JL, Pirkle JL, Makuc D, Neese JW, Bayse DD, Kovar MG. 1983. Chronological trend in blood lead levels between 1976 and 1980. N Engl J Med 308(23):1373-1377.
4. Arnett PA, Higginson CI, Voss WD, Bender WI, Wurst JM, Tippin JM. 1999. Depression in multiple sclerosis: relationship to working memory capacity. Neuropsychology 13(4): 546-556.
5. Baker EL, Feldman RG, White RF, Harley JP. 1983. The role of occupational lead exposure in the genesis of psychiatric and behavioral disturbances. Acta Psychiatr Scand Suppl 303:38-48.
6. Balbus-Kornfeld JM, Stewart W, Bolla KI, Schwartz BS 1995. Cumulative exposure to inorganic lead and neurobehavioural test performance in adults: an epidemiological review. Occup Environ Med 52(1):2-12
7. Barth A, Schaffer AW, Osterode W, Winker R, Konnaris C, Valic E, et al. 2002. Reduced cognitive abilities in lead-exposed men. Int Arch Occup Environ Health 75(6):394-398.
8. Birkenhager WH, Staessen JA. 2006. Progress in cardiovascular diseases: cognitive function in essential hypertension. Prog Cardiovasc Dis 49(1):1-10.
9. Bleecker ML, Ford DP, Lindgren KN, Hoese VM, Walsh KS, Vaughan CG. 2005. Differential effects of lead exposure on components of verbal memory. Occup Environ Med 62(3): 181-187.
10. Bleecker ML, Lindgren KN, Ford DP. 1997. Differential contribution of current and cumulative indices of lead dose to neuropsychological performance by age. Neurology 48(3):639-645.
11. Chia SE, Chia HP, Ong CN, Jeyaratnam J. 1997. Cumulative blood lead levels and neurobehavioral test performance. Neurotoxicology 18(3):793-803.
12. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, et al. 1993. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 261(5123):921-923.
13. Cory-Slechta DA. 1995 Relationships between lead-induced learning impairments and changes in dopaminergic, cholinergic, and glutamatergic neurotransmitter system functions. Annu Rev Pharmacol Toxicol 35:391-415.
14. Derogatis LR, Molisaratos N. 1983. The Brief Symptom Inventory: an introductory report. Psychol Med 13(3):595-605.
15. Dufouil C, Alperovitch A, Ducros V, Tzourio C. 2003. Homocysteine, white matter hyperintensities, and cognition in healthy elderly people. Ann Neurol 53(2):214-221.
16. Eichenbaum H. 2001. The hippocampus and declarative memory: cognitive mechanisms and neural codes. Behav Brain Res 127(1-2):199-207.
17. 2+ ion concentrations in cultured rat hippocampal neurons by a calmodulin-dependent mechanism Neurotoxicology 21(3):365-378.
18. Finkelstein Y, Markowitz ME, Rosen JF. 1998. Low-level lead-induced neurotoxicity in children: an update on central nervous system effects. Brain Res Rev 27(2):168-176.
19. Folstein MF, Folstein SE, McHugh PR, 1975. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12(3):189-198.
20. Glenn BS, Bandeen-Roche K, Lee BK, Weaver VM, Todd AC, Schwartz BS. 2006. Changes in systolic blood pressure associated with lead in blood and bone. Epidemiology 17(5):538-544.
21. Glenn BS, Stewart WF, Links JM, Todd AC, Schwartz BS. 2003. The longitudinal association of lead with blood pressure. Epidemiology 14(1):30-36.
22. Goodman M, LaVerda N, Clarke C, Foster ED, Iannuzzi J, Mandel J. 2002. Neurobehavioural testing in workers occupationally exposed to lead: systematic review and meta-analysis of publications. Occup Environ Med 59(4):217-223.
23. Goodman M, LaVerda N, Mandel J. 2001. Commentary on "A meta-analysis for neurobehavioural results due to occupational lead exposure with blood lead concentrations <70 microg/100 ml" by M. Meyer-Baron and A. Seeber. Arch Toxicol 75(7):439-442
24. Guallar E, Silbergeld EK, Navas-Acien A, Malhotra S, Astor BC, Sharrett AR, et al. 2006. Confounding of the relation between homocysteine and peripheral arterial disease by lead, cadmium, and renal function. Am J Epidemiol 163(8):700-708.
25. Hanninen H, Aitio A, Kovala T, Luukkonen R, Matikainen E, Mannelin T, et al. 1998. Occupational exposure to lead and neuropsychological dysfunction. Occup Environ Med 55(3): 202-209.
26. Hayden KM, Zandi PP, Lyketsos CG, Khachaturian AS, Bastian LA, Charoonruk G, et al. 2006. Vascular risk factors for incident Alzheimer disease and vascular dementia: the Cache County study. Alzheimer Dis Assoc Disord 20(2):93-100.
27. Hogervorst E, Ribeiro HM, Molyneux A, Budge M, Smith AD. 2002. Plasma homocysteine levels, cerebrovascular risk factors, and cerebral white matter changes (leukoaraiosis) in patients with Alzheimer disease. Arch Neurol 59(5):787-793.
28. Hoppin JA, Aro A, Hu H, Ryan PB. 2000. Measurement variability associated with KXRF bone lead measurement in young adults. Environ Health Perspect 108:239-242.
29. Hoppin JA, Aro AC, Williams PL, Hu H, Ryan PB. 1995. Validation of K-XRF bone lead measurement in young adults. Environ Health Perspect 103:78-83.
30. Hu H, Shih R, Rothenberg S, Schwartz BS. 2007. The epidemiology of lead toxicity in adults: measuring dose and consideration of other methodologic issues. Environ Health Perspect 115:455-462.
31. Jorm AF. 2000. Is depression a risk factor for dementia or cognitive decline? A review. Gerontology 46(4):219-227.
32. Kosnett MJ, Wedeen RP, Rothenberg SJ, Hipkins KL, Materna BL, Schwartz BS, et al. 2007. Recommendations for medical management of adult lead exposure. Environ Health Perspect 115:463-471.
33. Lindgren KN, Masten VL, Ford DP, Bleecker ML. 1996. Relation of cumulative exposure to inorganic lead and neuropsychological test performance. Occup Environ Med 53(7):472-477.
34. Links JM, Schwartz BS, Simon D, Bandeen-Roche K, Stewart WF. 2001. Characterization of toxicokinetics and toxicodynamics with linear systems theory: application to lead-associated cognitive decline. Environ Health Perspect 109(4):361-368.
35. Lucchini R, Albini E, Cortesi I, Placidi D, Bergamaschi E, Traversa F, et al. 2000. Assessment of neurobehavioral performance as a function of current and cumulative occupational lead exposure. Neurotoxicology 21(5):805-811.
36. Maizlish NA, Parra G, Feo O. 1995. Neurobehavioral evaluation of Venezuelan workers exposed to inorganic lead. Occup Environ Med 52:408-414.
37. Martin D, Glass TA, Bandeen-Roche K, Todd AC, Shi W, Schwartz BS. 2006. Association of blood lead and tibia lead with blood pressure and hypertension in a community sample of older adults. Am J Epidemiol 163(5):467-478.
38. Mayeux R, Ottman R, Maestre G, Ngai C, Tang MX, Ginsberg H, et al. 1995. Synergistic effects of traumatic head injury and apolipoprotein-epsilon 4 in patients with Alzheimer's disease. Neurology 45(3 pt 1):555-557.
39. McCaddon A, Hudson P, Hill D, Barber J, Lloyd A, Davies G, et al. 2003. Alzheimer's disease and total plasma aminothiols. Biol Psychiatry 53(3):254-260.
40. McCaddon A, Kelly CL. 1992. Alzheimer's disease: a 'cobalaminergic' hypothesis. Med Hypotheses 37(3):161-165.
41. McNair DM, Lorr M, Droppelman LF. 1971. Manual for the Profile of Mood States. San Diego, CA:Educational and Industrial Testing Service.
42. Meyer MR, Tschanz JT, Norton MC, Welsh-Bohmer KA, Steffens DC, Wyse BW, et al. 1998. APOE genotype predicts when - not whether - one is predisposed to develop Alzheimer disease. Nat Genet 19(4):321-322.
43. Meyer-Baron M, Seeber A. 2000. A meta-analysis for neuro-behavioural results due to occupational lead exposure with blood lead concentrations <70 microg/100 ml. Arch Toxicol 73(10-11):510-518.
44. Miyata M, Smith JD. 1996. Apolipoprotein E allele-specific antioxidant activity and effects on cytotoxicity by oxidative insults and beta-amyloid peptices. Nat Genet 14(1):55-61.
45. Moffat SD, Szekely CA, Zonderman AB, Kabani NJ, Resnick SM. 2000. Longitudinal change in hippocampal volume as a function of apolipoprotein E genotype. Neurology 55(1):134-136.
46. Naismith SL, Hickie IB, Turner K, Little CL, Winter V, Ward PB, et al. 2003. Neuropsychological performance in patients with depression is associated with clinical, etiological and genetic risk factors. J Clin Exp Neuropsychol 25(6):866-877.
47. Nash D, Magder L, Lustberg M, Sherwin RW, Rubin RJ, Kaufmann RB, et al. 2003. Blood lead, blood pressure, and hypertension in perimenopausal and postmenopausal women. JAMA 289(12):1523-1532.
48. National Library of Medicine. 2006. PubMed Database. Available: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed [accessed 24 August 2006].
49. Osterberg K, Borjesson J, Gerhardsson L, Schutz A, Skerfving S. 1997. A neurobehavioural study of long-term occupational inorganic lead exposure. Sci Total Environ 201(1):39-51.
50. Parnetti L, Bottiglieri T, Lowenthal D. 1997. Role of homocysteine in age-related vascular and non-vascular diseases. Aging (Milano) 9(4):241-257.
51. Payton M, Riggs KM, Spiro A, III, Weiss ST, Hu H. 1998. Relations of bone and blood lead to cognitive function: the VA Normative Aging Study. Neurotoxicol Teratol 20(1):19-27.
52. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. 1999. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 56(3):303-308.
53. Pirkle JL, Kaufmann RB, Brody DJ, Hickman T, Gunter EW, Paschal DC. 1998. Exposure of the U.S. population to lead, 1991-1994. Environ Health Perspect 106:745-750.
54. Poirier J, Sevigny P. 1998. Apolipoprotein E4, cholinergic integrity and the pharmacogenetics of Alzheimer's disease. J Neural Transm Suppl 53:199-207.
55. Radloff LS. 1977. The CES-D scale: a self report depression scale for research in the general population. Appl Psychol Measurement 1:385-401.
56. Ramesh GT, Manna SK, Aggarwal BB, Jadhav AL. 2001. Lead exposure activates nuclear factor kappa B, activator protein-1, c-Jun N-terminal kinase and caspases in the rat brain. Toxicol Lett 123(2-3):195-207.
57. Rhodes D, Spiro A III, Aro A, Hu H. 2003. Relationship of bone and blood lead levels to psychiatric symptoms: the normative aging study. J Occup Environ Med 45(11):1144-1151.
58. Salthouse TA. 1996. General and specific speed mediation of adult age differences in memory. J Gerontol B Psychol Sci Soc Sci 51(1):P30-42.
59. Salthouse TA. 1996. The processing-speed theory of adult age differences in cognition. Psychol Rev 103(3):403-428.
60. Saunders AM, Schmader K, Breitner JC, Benson MD, Brown WT, Goldfarb L, et al. 1993. Apolipoprotein E epsilon 4 allele distributions in late-onset Alzheimer's disease and in other amyloid-forming diseases. Lancet 342(8873):710-711.
61. Schafer JH, Glass TA, Bolla KI, Mintz M, Jedlicka AE, Schwartz BS. 2005a. Homocysteine and cognitive function in a population-based study of older adults. J Am Geriatr Soc 53(3): 381-388.
62. Schafer JH, Glass TA, Bressler J, Todd AC, Schwartz BS. 2005b. Blood lead is a predictor of homocysteine levels in a population-based study of older adults. Environ Health Perspect 113:31-35.
63. Schwartz BS, Lee BK, Bandeen-Roche K, Stewart W, Bolla K, Links J, et al. 2005. Occupational lead exposure and longitudinal decline in neurobehavioral test scores. Epidemiology 16(1):106-113.
64. Schwartz BS, Lee BK, Lee GS, Stewart WF, Lee SS, Hwang KY, et al. 2001. Associations of blood lead, dimercaptosuccinic acid-chelatable lead, and tibia lead with neurobehavioral test scores in South Korean lead workers. Am J Epidemiol 153(5):453-464.
65. Schwartz BS, Stewart W, Hu H. 2002. Neurobehavioural testing in workers occupationally exposed to lead. Occup Environ Med 59(9):648-649.
66. Schwartz BS, Stewart WF, Bolla KI, Simon PD, Bandeen-Roche K, Gordon PB, et al. 2000. Past adult lead exposure is associated with longitudinal decline in cognitive function. Neurology 55(8):1144-1150.
67. Seeber A, Meyer-Baron M. 2003. Neurobehavioural testing in workers occupationally exposed to lead. Occup Environ Med 60(2):145; author reply 145-146.
68. Seeber A, Meyer-Baron M, Schaper M. 2002. A summary of two meta-analyses on neurobehavioural effects due to occupational lead exposure. Arch Toxicol 76(3):137-145.
69. Selley ML. 2003. Increased concentrations of homocysteine and asymmetric dimethylarginine and decreased concentrations of nitric oxide in the plasma of patients with Alzheimer's disease. Neurobiol Aging 24(7):903-907.
70. Shih RA, Glass TA, Bandeen-Roche K, Carlson MC, Bolla KI, Todd AC, et al. 2006. Environmental lead exposure and cognitive function in community-dwelling older adults. Neurology 67(9):1556-1562.
71. Skoog I, Gustafson D. 2006. Update on hypertension and Alzheimer's disease. Neurol Res 28(6):605-611.
72. Stewart WF, Schwartz BS, Davatzikos C, Shen O, Liu D, Wu X, et al. 2006. Past adult lead exposure is linked to neurodegeneration measured by brain MRI Neurology 66(10):1476-1484.
73. Stewart WF, Schwartz BS, Simon D, Bolla KI, Todd AC, Links J, 1999. Neurobehavioral function and tibial and chelatable lead levels in 543 former organolead workers. Neurology 52(8):1610-1617.
74. Stewart WF, Schwartz BS, Simon D, Kelsey K, Todd AC. 2002. ApoE genotype, past adult lead exposure, and neurobehavioral function. Environ Health Perspect 110:501-505.
75. Stokes L, Letz R, Garr F, Kolczalk M, McNeill FE, Chettle DR, et al. 1998. Neurotoxicity in young adults 20 years after childhood exposure to lead: the Bunker Hill experience. Occup Environ Med 55(8):507-516.
76. Teter B, Xu PT, Gilbert JR, Roses AD, Galasko D, Cole GM. 1999. Human apolipoprotein E isoform-specific differences in neuronal sprouting in organotypic hippocampal culture. J Neurochem 73(6):2613-2616.
77. Weingartner H, Cohen RM, Murphy DL, Martello J, Gerdt C. 1981. Cognitive processes in depression. Arch Gen Psychiatry 38(1):42-47.
78. Weiss B, Bellinger DC. 2006. Social ecology of children's vulnerability to environmental pollutants. Environ Health Perspect 114:1479-1485.
79. Weisskopf MG, Proctor SP, Wright RO, Schwartz J, Spiro A III, Sparrow D, et al. 2007. Cumulative lead exposure and cognitive performance among elderly men. Epidemiology 18(1):59-56.
80. Weisskopf MG, Wright RO, Schwartz J, Spiro A III, Sparrow D, Aro A, et al 2004. Cumulative lead exposure and prospective change in cognition among elderly men: the VA Normative Aging Study. Am J Epidemiol 160(12):1184-1193.
81. Widzowski DV, Cory-Slechta DA. 1994. Homogeneity of regional brain lead concentrations. Neurotoxicology 15(2):295-307.
82. Wilson RS, Beckett LA, Barnes LL, Schneider JA, Bach J, Evans DA, et al. 2002. Individual differences in rates of change in cognitive abilities of older persons. Psychol Aging 17(2): 179-193.
83. Wright RO, Tsaih SW, Schwartz J, Spiro A III, McDonald K, Weiss ST, et al. 2003. Lead exposure biomarkers and mini-mental status exam scores in older men. Epidemiology 14(6):713-718.
84. Yankner BA. 1996. Mechanisms of neuronal degeneration in Alzheimer's disease. Neuron 16(5):921-932.
85. Zawia NH, Crumpton T, Brydie M, Reddy GR, Razmiafshari M. 2000. Disruption of the zinc finger domain: a common target that underlies many of the effects of lead. Neurotoxicology 21(6):1069-1080.
86. Zubenko GS, Stiffler S, Stabler S, Kopp U, Hughes HB, Cohen BM, et al. 1994. Association of the apolipoprotein E epsilon 4 allele with clinical subtypes of autopsy-confirmed Alzheimer's disease. Am J Med Genet 54(3):199-205.